For example, IMA-950 (multi-peptide vaccine composed of 9 MHC class I and 2 MHC class II peptides), with poly-ICLC, was recently tested in a phase I clinical trial and resulted in patients developing tumor peptide-specific CD4+ and CD8+ T cell responses, with the IMA-950 antigens remaining stably expressed on the tumor throughout the course of the disease [67]. This evidence concerns the gene CD4 and neoplasm.